Answers are grounded in this paper and cite their sources.
SUMMARY Decisions concerning the use of allogeneic red blood cell (RBC) transfusion in the treatment of anemia and hemorrhage require a clear understanding of the risks and benefits of both the condition and its treatment. Although we have developed a much clearer appreciation for the infectious and immunomodulatory risks of RBC transfusion over the past two decades, the risks of anemia in many clinical settings and the benefits of RBC transfusion are still inadequately characterized. Only one large randomized controlled trial has examined red cell administration in the perioperative and in the critical care setting, and high‐quality clinical evidence is not yet available for many decisions related to red cell transfusions. Several studies and initiatives to evaluate alternatives to RBC transfusions and to improve current understanding of transfusion practices are underway. It is anticipated that risks and benefits of red cells and alternatives will be elucidated in the coming years.
No takes yet. Share an insight, caveat, or question.
Hébert et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: